Augmentation by escitalopram, but not citalopram or R-citalopram, of the effects of low-dose risperidone: Behavioral, biochemical, and electrophysiological evidence

Synapse

Volumn 66, Issue 4, 2012, Pages 277-290

  Marcus, Monica M ^a   Jardemark, Kent ^a   Malmerfelt, Anna ^a   Gertow, Jens ^a   Konradsson Geuken, Åsa ^a   Svensson, Torgny H ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antipsychotic; Dopamine; Electrophysiology; Glutamate; SSRI

Indexed keywords

CITALOPRAM; DOPAMINE; ESCITALOPRAM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; R CITALOPRAM; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; BRAIN ELECTROPHYSIOLOGY; CATALEPSY; CONDITIONED AVOIDANCE RESPONSE TEST; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; EXTRAPYRAMIDAL SYMPTOM; IN VIVO STUDY; LOW DRUG DOSE; MICRODIALYSIS; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CITALOPRAM; DOPAMINE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ELECTROPHYSIOLOGICAL PHENOMENA; MALE; MICRODIALYSIS; PATCH-CLAMP TECHNIQUES; RATS; RATS, WISTAR; RISPERIDONE; SEROTONIN UPTAKE INHIBITORS;

EID: 84856391332     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.21510     Document Type: Article

References (90)

1. Akbarian S, Sucher NJ, Bradley D, Tafazzoli A, Trinh D, Hetrick WP, Potkin SG, Sandman CA, Bunney WEJr, Jones EG. 1996. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 16: 19-30.
2. Alaerts M, Del-Favero J. 2009. Searching genetic risk factors for schizophrenia and bipolar disorder: Learn from the past and back to the future. Hum Mutat 30: 1139-1152.
3. Arborelius L, Chergui K, Murase S, Nomikos GG, Hook BB, Chouvet G, Hacksell U, Svensson TH. 1993a. The 5-HT1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn Schmiedebergs Arch Pharmacol 347: 353-362.
4. Arborelius L, Nomikos GG, Hacksell U, Svensson TH. 1993b. (R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex. Acta Physiol Scand 148: 465-466.
5. Bell MD, Zito W, Greig T, Wexler BE. 2008. Neurocognitive enhancement therapy with vocational services: Work outcomes at two-year follow-up. Schizophr Res 105: 18-29.
6. Beneyto M, Meador-Woodruff JH. 2008. Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology 33: 2175-2186.
7. Berk M, Ichim C, Brook S. 2001. Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study. Int Clin Psychopharmacol 16: 87-92.
8. Blackwood DH, Pickard BJ, Thomson PA, Evans KL, Porteous DJ, Muir WJ. 2007. Are some genetic risk factors common to schizophrenia, bipolar disorder and depression? Evidence from DISC1, GRIK4 and NRG1. Neurotox Res 11: 73-83.
9. Bortolozzi A, Diaz-Mataix L, Scorza MC, Celada P, Artigas F. 2005. The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity. J Neurochem 95: 1597-1607.
10. Brosen K, Naranjo CA. 2001. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol 11: 275-283.
11. Buckley PF. 2008. Update on the treatment and management of schizophrenia and bipolar disorder. CNS Spectr 13: 1-10.
12. Castner SA, Williams GV. 2007. Tuning the engine of cognition: A focus on NMDA/D1 receptor interactions in prefrontal cortex. Brain Cogn 63: 94-122.
13. Chamberlain SR, Muller U, Blackwell AD, Clark L, Robbins TW, Sahakian BJ. 2006. Neurochemical modulation of response inhibition and probabilistic learning in humans. Science 311: 861-863.
14. Chen L, Yang CR. 2002. Interaction of dopamine D1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex. J Neurophysiol 87: 2324-2336.
15. Chen G, Greengard P, Yan Z. 2004. Potentiation of NMDA receptor currents by dopamine D1 receptors in prefrontal cortex. Proc Natl Acad Sci USA 101: 2596-2600.
16. Chergui K, Charlety PJ, Akaoka H, Saunier CF, Brunet JL, Buda M, Svensson TH, Chovet G. 1993. Tonic activation of NMDA receptors causes spontaneous burst discharge of rat midbrain dopamine neurons in vivo. Eur J Neurosci 5: 137-144.
17. Croxtall JD, Scott LJ. 2010. Olanzapine/fluoxetine: A review of its use in patients with treatment-resistant major depressive disorder. CNS Drugs 24: 245-262.
18. Davis JM, Chen N, Glick ID. 2003. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60: 553-564.
19. Davis KL, Kahn RS, Ko G, Davidson M. 1991. Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatry 148: 1474-1486.
20. Deeks ED, Keating GM. 2008. Olanzapine/fluoxetine: A review of its use in the treatment of acute bipolar depression. Drugs 68: 1115-1137.
21. Deutch AY, Clark WA, Roth RH. 1990. Prefrontal cortical dopamine depletion enhances the responsiveness of mesolimbic dopamine neurons to stress. Brain Res 521: 311-315.
22. Dunlop BW, Nemeroff CB. 2007. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 64: 327-337.
23. El Mansari M, Wiborg O, Mnie-Filali O, Benturquia N, Sanchez C, Haddjeri N. 2007. Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: In-vitro and in-vivo studies. Int J Neuropsychopharmacol 10: 31-40.
24. Eltayb A, Wadenberg ML, Svensson TH. 2005. Enhanced cortical dopamine output and antipsychotic-like effect of raclopride with adjunctive low-dose L-dopa. Biol Psychiatry 58: 337-343.
25. Gefvert O, Eriksson B, Persson P, Helldin L, Bjorner A, Mannaert E, Remmerie B, Eerdekens M, Nyberg S. 2005. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int J Neuropsychopharmacol 8: 27-36.
26. Goldman-Rakic PS, Muly IIIEC, Williams GV. 2000. D(1) receptors in prefrontal cells and circuits. Brain Res Brain Res Rev 31: 295-301.
27. Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV. 2004. Targeting the dopamine D(1) receptor in schizophrenia: Insights for cognitive dysfunction. Psychopharmacology (Berl) 174: 3-16.
28. Green MF, Kern RS, Heaton RK. 2004. Longitudinal studies of cognition and functional outcome in schizophrenia: Implications for MATRICS. Schizophr Res 72: 41-51.
29. Herrera-Guzman I, Herrera-Abarca JE, Gudayol-Ferre E, Herrera-Guzman D, Gomez-Carbajal L, Pena-Olvira M, Villuendas-Gonzalez E, Joan GO. 2010. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder. Psychiatry Res 177: 323-329.
30. Hertel P, Fagerquist MV, Svensson TH. 1999. Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science 286: 105-107.
31. Jardemark KE, Liang X, Arvano V, Wang RY. 2000. Subchronic treatment with either clozapine, olanzapine or haloperidol produces a hyposensitive response of the rat cortical cells to N-methyl-D-aspartate. Neuroscience 100: 1-9.
32. Jardemark K, Ninan I, Svensson TH, Wang RY. 2002. Differential effects of atypical and typical antipsychotic drugs on NMDA-receptor-mediated neurotransmission in pyramidal cells of the rat medial prefrontal cortex. Nord J Psychiatry 56: 20.
33. Jaskiw GE, Popli AP. 2004. A meta-analysis of the response to chronic L-dopa in patients with schizophrenia: Therapeutic and heuristic implications. Psychopharmacology (Berl) 171: 365-374.
34. Javitt DC. 2010. Glutamatergic theories of schizophrenia. Isr J Psychiatry Relat Sci 47: 4-16.
35. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL. 2008. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 33: 2303-2312.
36. Joffe G, Terevnikov V, Joffe M, Stenberg JH, Burkin M, Tiihonen J. 2009. Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: A double-blind, randomized, placebo-controlled trial. Schizophr Res 108: 245-251.
37. Kang S, Kim HJ, Kim HJ, Shin SK, Choi SH, Lee MS, Shin KH. 2010. Effects of reboxetine and citalopram pretreatment on changes in cocaine and amphetamine regulated transcript (CART) expression in rat brain induced by the forced swimming test. Eur J Pharmacol 647: 110-116.
38. Kapur S, Mamo D. 2003. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27: 1081-1090.
39. Keating GM, Robinson DM. 2007. Quetiapine: A review of its use in the treatment of bipolar depression. Drugs 67: 1077-1095.
40. Kolachana BS, Saunders RC, Weinberger DR. 1995. Augmentation of prefrontal cortical monoaminergic activity inhibits dopamine release in the caudate nucleus: An in vivo neurochemical assessment in the rhesus monkey. Neuroscience 69: 859-868.
41. Konradsson A, Marcus MM, Hertel P, Svensson TH, Jardemark KE. 2006. Inhibition of the glycine transporter GlyT-1 potentiates the effect of risperidone, but not clozapine, on glutamatergic transmission in the rat medial prefrontal cortex. Synapse 60: 102-108.
42. Kugelberg FC, Apelqvist G, Carlsson B, Ahlner J, Bengtsson F. 2001. In vivo steady-state pharmacokinetic outcome following clinical and toxic doses of racemic citalopram to rats. Br J Pharmacol 132: 1683-1690.
43. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. 2009. Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet 373: 31-41.
44. Leysen JE. 2000. Receptor profiles of antipsychotics. In: Ellenbroek BA, Cools AR. editors. Atypical antipsychotics. Basel/Switzerland: Birkhauser Verlag. p 57-81.
45. Li CC. 1964. Change-over design. Introduction to experimental statistics. New York: McGraw-Hill Book Company, p 207-226.
46. Linner L, Wiker C, Wadenberg ML, Schalling M, Svensson TH. 2002. Noradrenaline reuptake inhibition enhances the antipsychotic-like effect of raclopride and potentiates D-2-blockage-induced dopamine release in the medial prefrontal cortex of the rat. Neuropsychopharmacology 27: 691-698.
47. Litman RE, Su TP, Potter WZ, Hong WW, Pickar D. 1996. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. Br J Psychiatry 168: 571-579.
48. Mannens G, Meuldermans W, Snoeck E, Heykants J. 1994. Plasma protein binding of risperidone and its distribution in blood. Psychopharmacology (Berl) 114: 566-572.
49. Marcus MM, Jardemark KE, Wadenberg ML, Langlois X, Hertel P, Svensson TH. 2005. Combined alpha2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat. Int J Neuropsychopharmacol 8: 315-327.
50. Marcus MM, Jardemark K, Malmerfelt A, Bjorkholm C, Svensson TH. 2010a. Reboxetine enhances the olanzapine-induced antipsychotic-like effect, cortical dopamine outflow and NMDA receptor-mediated transmission. Neuropsychopharmacology 35: 1952-1961.
51. Marcus MM, Wiker C, Franberg O, Konradsson-Geuken A, Langlois X, Jardemark K, Svensson TH. 2010b. Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission. Int J Neuropsychopharmacol 13: 891-903.
52. McIntyre RS, Soczynska JK, Woldeyohannes HO, Alsuwaidan M, Konarski JZ. 2007. A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmacother 8: 1211-1219.
53. Medori R, Mannaert E, Grunder G. 2006. Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. Eur Neuropsychopharmacol 16: 233-240.
54. Meltzer HY, Huang M. 2008. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res 172: 177-197.
55. Mnie-Filali O, Faure C, Mansari ME, Lambas-Senas L, Berod A, Zimmer L, Sanchez C, Haddjeri N. 2007. R-citalopram prevents the neuronal adaptive changes induced by escitalopram. Neuroreport 18: 1553-1556.
56. Moghaddam B, Bunney BS. 1990. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: An in vivo microdialysis study. J Neurochem 54: 1755-1760.
57. Montgomery SA, Baldwin DS, Blier P, Fineberg NA, Kasper S, Lader M, Lam RW, Lepine JP, Moller HJ, Nutt DJ, Rouillon F, Schatzberg AF, Thase ME. 2007. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 22: 323-329.
58. Mork A, Kreilgaard M, Sanchez C. 2003. The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 45: 167-173.
59. Murase S, Grenhoff J, Chouvet G, Gonon FG, Svensson TH. 1993. Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic dopamine neurons studied in vivo. Neurosci Lett 157: 53-56.
60. Ninan I, Wang RY. 2003. Modulation of the ability of clozapine to facilitate NMDA- and electrically evoked responses in pyramidal cells of the rat medial prefrontal cortex by dopamine: Pharmacological evidence. Eur J Neurosci 17: 1306-1312.
61. Ninan I, Jardemark KE, Wang RY. 2003. Differential effects of atypical and typical antipsychotic drugs on N-methyl-D-aspartate- and electrically evoked responses in the pyramidal cells of the rat medial prefrontal cortex. Synapse 48: 66-79.
62. Nomikos GG, Iurlo M, Andersson JL, Kimura K, Svensson TH. 1994. Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology (Berl) 115: 147-156.
63. Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L. 1999. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry 156: 869-875.
64. Nyberg S, Takano A, Jucaite A, Karlsson P, McCarthy D, Kagedal M, Eriksson H, Lee CM, Halldin C, Farde L. 2008. PET-measured occupancy of the norepinephrene transporter by extended release quetiapine fumarate (quetiapine XR) in brains of healthy subjects. Eur Neuropsychopharmacol 18: S270.
65. Paxinos G, Watson C. 1998. The rat brain in stereotaxic coordinates. 4th ed. San Diego, CA: Academic Press.
66. Poyurovsky M, Koren D, Gonopolsky I, Schneidman M, Fuchs C, Weizman A, Weizman R. 2003. Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: An add-on, double-blind placebo-controlled study. Eur Neuropsychopharmacol 13: 123-128.
67. Raedler TJ, Jahn H, Arlt J, Kiefer F, Schick M, Naber D, Wiedemann K. 2004. Adjunctive use of reboxetine in schizophrenia. Eur Psychiatry 19: 366-369.
68. Sanchez C. 2006. The pharmacology of citalopram enantiomers: The antagonism by R-citalopram on the effect of S-citalopram. Basic Clin Pharmacol Toxicol 99: 91-95.
69. Saunders RC, Kolachana BS, Bachevalier J, Weinberger DR. 1998. Neonatal lesions of the medial temporal lobe disrupt prefrontal cortical regulation of striatal dopamine. Nature 393: 169-171.
70. Schilström B, Konradsson-Geuken A, Ivanov V, Gertow J, Feltmann K, Marcus MM, Jardemark K, Svensson TH. 2011. Effects of S-citalopram, citalopram and R-citalopram on the firing patterns of dopamine neurons in the ventral tegmental area, NMDA receptor-mediated transmission in the medial prefrontal cortex and cognitive function in the rat. Synapse 65: 357-367.
71. Schotte A, Janssen PF, Gommeren W, Luyten WH, van Gompel P, Lesage AS, de Loore K, Leysen JE. 1996. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology (Berl) 124: 57-73.
72. Shahid M, Walker GB, Zorn SH, Wong EH. 2009. Asenapine: A novel psychopharmacologicagent with a unique human receptor signature. J Psychopharmacol 23: 65-73.
73. Shobo M, Kondo Y, Yamada H, Mihara T, Yamamoto N, Katsuoka M, Harada K, Ni K, Matsuoka N. 2010. Norzotepine, a major metabolite of zotepine, exerts atypical antipsychotic-like and antidepressant-like actions through its potent inhibition of norepinephrine reuptake. J Pharmacol Exp Ther 333: 772-781.
74. Silver H. 2004. Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Expert Opin Pharmacother 5: 2053-2058.
75. Stone JM, Morrison PD, Pilowsky LS. 2007. Glutamate and dopamine dysregulation in schizophrenia-A synthesis and selective review. J Psychopharmacol 21: 440-452.
76. Storustovu S, Sanchez C, Porzgen P, Brennum LT, Larsen AK, Pulis M, Ebert B. 2004. R-citalopram functionally antagonises escitalopram in vivo and in vitro: Evidence for kinetic interaction at the serotonin transporter. Br J Pharmacol 142: 172-180.
77. Svensson TH. 2000. Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs. Brain Res Brain Res Rev 31: 320-329.
78. Uchida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, Mamo DC. 2011. Predicting dopamine D receptor occupancy from plasma levels of antipsychotic drugs: A systematic review and pooled analysis. J Clin Psychopharmacol 31: 318-325.
79. Uher R, Maier W, Hauser J, Marusic A, Schmael C, Mors O, Henigsberg N, Souery D, Placentino A, Rietschel M, Zobel A, Dmitrzak-Weglarz M, Petrovic A, Jorgensen L, Kalember P, Giovannini C, Barreto M, Elkin A, Landau S, Farmer A, Aitchison KJ, McGuffin P. 2009. Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. Br J Psychiatry 194: 252-259.
80. Wadenberg ML. 2010. Conditioned avoidance response in the development of new antipsychotics. Curr Pharm Des 16: 358-370.
81. Wadenberg ML, Kapur S, Soliman A, Jones C, Vaccarino F. 2000. Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology (Berl) 150: 422-429.
82. Wadenberg M-LG, Soliman A, VanderSpek SC, Kapur S. 2001. Dopamine d(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 25: 633-641.
83. Wadenberg ML, Wiker C, Svensson TH. 2007. Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive alpha2 adrenoceptor blockade: Experimental evidence. Int J Neuropsychopharmacol 10: 191-202.
84. Wiker C, Linner L, Wadenberg ML, Svensson TH. 2005. Adjunctive treatment with mianserin enhances effects of raclopride on cortical dopamine output and, in parallel, its antipsychotic-like effect. Neuropsychiatr Dis Treat 1: 253-260.
85. Wille SM, Cooreman SG, Neels HM, Lambert WE. 2008. Relevant issues in the monitoring and the toxicology of antidepressants. Crit Rev Clin Lab Sci 45: 25-89.
86. Wirkner K, Krause T, Koles L, Thummler S, Al-Khrasani M, Illes P. 2004. D(1) but not D(2) dopamine receptors or adrenoceptors mediate dopamine-induced potentiation of N-methyl-D-aspartate currents in the rat prefrontal cortex. Neurosci Lett 372: 89-93.
87. Wong EH, Tarazi FI, Shahid M. 2010. The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action. Pharmacol Ther 126: 173-185.
88. Wroolie TE, Williams KE, Keller J, Zappert LN, Shelton SD, Kenna HA, Reynolds MF, Rasgon NL. 2006. Mood and neuropsychological changes in women with midlife depression treated with escitalopram. J Clin Psychopharmacol 26: 361-366.
89. Yang CR, Seamans JK, Gorelova N. 1996. Electrophysiological and morphological properties of layers V-VI principal pyramidal cells in rat prefrontal cortex in vitro. J Neurosci 16: 1904-1921.
90. Zhong H, Hansen KB, Boyle NJ, Han K, Muske G, Huang X, Egebjerg J, Sanchez C. 2009. An allosteric binding site at the human serotonin transporter mediates the inhibition of escitalopram by R-citalopram: Kinetic binding studies with the ALI/VFL-SI/TT mutant. Neurosci Lett 462: 207-212.